Chemo Experts, the easiest way to learn about cancer treatment
Find a Treatment:
Cancer Types

Treatment Name: HyperCVAD Part A + Dasatinib (Sprycel®)

HyperCVAD Part A + Dasatinib (Sprycel®) is a Chemotherapy Regimen for Acute Lymphoid Leukemia (ALL)

Thank you for visiting our HyperCVAD Part A + Dasatinib (Sprycel®) page.

  • If you are interested in seeing the full treatment regimen page for HyperCVAD Part A + Dasatinib (Sprycel®) sooner rather than later, please cast your vote for HyperCVAD Part A + Dasatinib (Sprycel®).
  • Votes from users like you are important as they help us prioritize the order in which we build our content. The more requests we receive, the faster we will build it!

While we work on uploading the pages that matter to you most, we hope that links to journal article references for HyperCVAD Part A + Dasatinib (Sprycel®) shown below will prove useful in the meantime.

Thank you for your continued support!

The ChemoExperts Team


1) Ravandi F, O'Brien S, Thomas D, et al. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood. 2010;116:2070-2077.

2) Ohad B, Dumlao TL, Kantarjian H, et al. Phase II trial of HyperCVAD and Dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia. Am J Hematol. 2014;89:282-287.

Created: February 18, 2019 Updated: February 18, 2019

What is Acute Lymphoid Leukemia (ALL)?

Acute Lymphoid Leukemia (ALL), also known as acute lymphoblastic leukemia, is a disease of the lymphoid cells found in the bone marrow. Lymphoid cells are responsible for developing into cells of the immune system called B-cells, T-cells, or Natural Killer cells. In ALL, immature lymphoid cells know as "blasts" replicate at a very fast rate. Sometimes blasts crowd out the normal cells in the bone marrow so that red blood cells or platelets are unable to develop.

Common symptoms of ALL include fatigue, infection, and bruising or bleeding. ALL is the most common cancer diagnosed in children, but is rare in adults. Most cases of ALL are considered "de novo" meaning that the cause is unknown; however, some cases can be linked to certain genetic syndromes. There is no staging system for ALL. Chromosomes are often analyzed to determine which mutations in the chromosomes exist. The effectiveness of the treatment may depend upon the specific chromosome mutations that are present.

NOTE: Treatment Options listed below are not all-inclusive. Other treatments may be available. ChemoExperts provides drug information and does not recommend any one treatment over another. Only your Doctor can choose your therapy.

Common HyperCVAD Part A + Dasatinib (Sprycel®) starting doses

  • Cyclophosphamide 300 mg/m2 intravenous (I.V.) infusion, usually given over 3 hours, every 12 hours (twice daily) on Days 1, 2, and 3 (six doses total)
  • Mesna 600 mg/m2 I.V. infusion, usually given over 24 hours on Days 1, 2, and 3, ending on Day 4
  • Vincristine 2 mg I.V. infusion, usually given over 15 minutes on Days 4 and 11
  • Doxorubicin 50 mg/m2 I.V. infusion, given over 2 - 24 hours (infusion time depends upon hospital guidelines) on Day 4
  • Dexamethasone 40 mg (ten x 4 mg) oral tablet by mouth on Days 1, 2, 3, 4 and 11, 12, 13, 14
  • Dasatinib 100 mg by mouth once daily on Days 1 through 14 of Cycle 1, then 70 mg by mouth once daily continuously for all subsequent cycles